fda glp 1 compounding GLP-1 Compounding: When Innovation May Mean Liability Navigating Access: The Future of
Description
9 Use of DPP4-inhibitors in older frail populations Oral DPP-4 inhibitors have few notable side effects and are associated with a minimal risk of hypoglycaemia
If exenatide access becomes limited, your care team can identify therapeutically comparable GLP-1 agents
Because of these risks, healthcare providers may recommend medical treatment when lifestyle changes alone have not produced sufficient results
It is important to note that most available data reflect relatively short to medium-term exposure (typically under five years)
Studies in humans should be done (42, 43) ( Table 1 )
J., Rahman, M
